Recent News

Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer

Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021

Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference

Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition
EMPTY api-answer: No JSON received - is the API down? Check the URL you use in the shortcode!

CORRECTION: Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.

Learn more

Investors

View press releases, events and presentations, and other investment information

Learn more

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.

Learn more